WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body. Vandetanib was approved by the U.S. Food and Drug Administration on April 6, 2011 and is available exclusively through the pharmacy business unit of Biologics, Inc., an integrated oncology management company.
